Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 3, 2005, Pages 638-642

  Baida, Aida ^a   Farrington, Susan M ^b   Galofré, Pere ^c   Marcos, Ricard ^a   Velázquez, Antonia ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HYDROXYSTEROID DEHYDROGENASE; PROTEIN BAT 40; THYROID HORMONE RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CHROMOSOME 1; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENETIC MARKER; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SPAIN; THYROID CANCER;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; THYROID HORMONE RECEPTORS ALPHA; THYROID NEOPLASMS;

EID: 16844372592     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0424     Document Type: Article

References (50)

1. Ponder BA. Cancer genetics. Nature 2001;411:336-41.
2. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003;33:238-44.
3. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
4. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev 1994;15:202-32.
5. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
6. Kazakov VS, Demidchik EP, Astakhova LN. Thyroid cancer after Chernobyl. Nature 1992;359:421.
7. Farid NR. Molecular pathogenesis of thyroid cancer: the significance of oncogenes, tumor suppressor genes, and genomic instability. Exp Clin Endocrinol Diabetes 1996;104:1-12.
8. Hunt JL. Molecular mutations in thyroid carcinogenesis. Am J Clin Pathol 2002;118:S116-27.
9. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4: 159-64.
10. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
11. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
12. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
13. Ito T, Seyama T, Mizuno T, et al. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 1993;84: 526-31.
14. Giuffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 1998;9:695-701.
15. Vecchio G, Santoro M. Oncogenes and thyroid cancer. Clin Chem Lab Med 2000;38:113-6.
16. Wallin G, Bronnegard M, Grimelius L, McGuire J, Torring O. Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue. Thyroid 1992;2:307-13.
17. Onda M, Li D, Suzuki S, et al. Expansion of microsatellite in the thyroid hormone receptor-α1 gene linked to increased receptor expression and less aggressive thyroid cancer. Clin Cancer Res 2002;8:2870-4.
18. Laudet V, Begue A, Henry-Duthoit C, et al. Genomic organization of the human thyroid hormone receptor α (c-erbA-1) gene. Nucleic Acids Res 1991; 19:1105-12.
19. Tung WS, Shevlin DW, Kaleem Z, Tribune DJ, Wells SA Jr, Goodfellow PJ. Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer 1997;19:43-51.
20. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000;27:244-51.
21. Kleer CG, Bryant BR, Giordano TJ, Sobel M, Merino MJ. Genetic changes in chromosomes 1p and 17p in thyroid cancer progression. Endocr Pathol 2000;11:137-43.
22. Kjellman P, Lagercrantz S, Hoog A, Wallin G, Larsson C, Zedenius J. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes Cancer 2001;32:43-9.
23. Roque L, Nunes VM, Ribeiro C, Martins C, Scares J. Karyotypic characterization of papillary thyroid carcinomas. Cancer 2001;92:2529-38.
24. Stoler DL, Datta RV, Charles MA, et al. Genomic instability measurement in the diagnosis of thyroid neoplasms. Head Neck 2002;24:290-5.
25. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 2002;161:1549-56.
26. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002;62:1784-9.
27. Lachance Y, Luu-The V, Labrie C, et al. Characterization of human 3beta-hydroxysteroid dehydrogenase/delta5-delta4-isomerase gene and its expression in mammalian cells. J Biol Chem 1990;265:20469-75.
28. McBride MW, McVie AJ, Burridge SM, et al. Cloning, expression, and physical mapping of the 3β-hydroxysteroid dehydrogenase gene cluster (HSD3BP1-HSD3BP5) in human. Genomics 1999;1:277-84.
29. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249-60.
30. Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2002;37:241-56.
31. Lillie EO, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003;5:164-73.
32. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003;149:469-77.
33. Farahati J, Demidchik EP, Biko J, Reiners C. Inverse association between age at the time of radiation exposure and extent of disease in cases of radiation-induced childhood thyroid carcinoma in Belarus. Cancer 2000; 88:1470-6.
34. Frentzel-Beyme R, Helmert U. Association between malignant tumors of the thyroid gland and exposure to environmental protective and risk factors. Rev Environ Health 2000;15:337-58.
35. Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol 2002;3:269-79.
36. Hernandez A, Cespedes W, Xamena N, et al. Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett 2003;190:37-44.
37. Matakidou A, Hamel N, Polpat S, et al. Risk of non-medullary thryoid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis 2004;25:369-73.
38. Onda M, Nakamura I, Suzuki S, et al. Microsatellite instability in thyroid cancer: hot spots, clinicopathological implications, and prognostic significance. Clin Cancer Res 2001;7:3444-9.
39. Liu B, Farrington SM, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995;1:348-52.
40. Sakurai A, Bell GI, DeGroot LJ. Dinucleotide repeat polymorphism in the human thyroid hormone receptor α gene (THRA1) on chromosome 17. Hum Mol Genet 1992;1:553.
41. Saatcioglu F, Deng T, Karin M. A novel cis element mediating ligand-independent activation by c-ErbA: implications for hormonal regulation. Cell 1993;75:1095-105.
42. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996;10: 1167-77.
43. Dellovade TL, Chan J, Vennstrom B, Forrest D, Pfaff DW. The two thyroid hormone receptor genes have opposite effects on estrogen-stimulated sex behaviors. Nat Neurosci 2000;3:472-5.
44. Zhou XP, Hoang JM, Cottu P, Thomas G, Hamelin R. Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors. Oncogene 1997;15: 1713-8.
45. Samowitz WS, Slattery ML, Potter JD, Leppert MF. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am J Pathol 1999;154:1637-41.
46. Yokozaki H. Distribution of germline BAT-40 poly-adenine tract microsatellite variants in the Japanese. Int J Mol Med 2000;6:445-8.
47. Bacon A, Dunlop MG, Farrington SM. Hypermutability at a poly(A/T) tract in the human germline. Nucleic Acids Res 2000;29:4405-13.
48. Mukherjee M, Vaish M, Mittal RD, Mitral B. Allelic variation of BAT-26 and BAT-40 poly-adenine repeat loci in North Indians. Int J Mol Med 2002; 9:91-4.
49. Farrall M, Weeks DE. Mutational mechanisms for generating microsatellite allele-frequency distributions: an analysis of 4,558 markers. Am J Hum Genet 1998;62:1260-2.
50. Ellegren H. Heterogeneous mutation processes in human microsatellite DNA sequences. Nat Genet 2000;24:400-2.